Tag Archives: Aducanumab

Biogen’s poster presentation for Alzheimer’s candidate hardly noticed at London AAIC meeting as market focuses on quarterly results instead; start accumulating.

Biogen Inc. (Cambridge MA) laid out long-term plans to strengthen its core multiple sclerosis (MS) business, develop more neuroscience drugs and shop for late-stage assets, after reporting robust second-quarter results,… Read more »



New Biogen pick for CEO inherits tough job; markets aren’t exactly enthralled–yet

Biogen Inc. (Cambridge MA) said Monday (December 19, 2016) it has named veteran biopharmaceutical executive Michel Vounatsos, head of the company’s commercial organization, its next chief executive. Mr. Vounatsos will succeed George Scangos, who announced earlier this… Read more »



Lilly Alzheimer’s drug, like so many others, fails; will true breakthrough happen this century?

Eli Lilly & Co. (Indianapolis RIN) said its experimental Alzheimer’s treatment failed to slow loss of cognitive ability in patients with mild symptoms, a major setback for the company and millions of… Read more »



Study Suggests Revolutionary Drug Could Benefit Patients with Early Stage Alzheimer’s

A trial of a new Alzheimer’s drug has shown it could benefit patients in the earliest stages of the disease, raising hopes that a treatment for the devastating condition may… Read more »